Loading
institutionsInstitution
Sun Yat-sen University Cancer Center
Sun Yat-sen University Cancer Center is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma and a top enroller for Chinese ADC and PD-1 trials.
Overview
Sun Yat-sen University Cancer Center in Guangzhou is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma, and a top enroller for Chinese antibody-drug conjugate and PD-1 trials; it ranks sixtieth in the Newsweek/Statista oncology list. Jun Ma's group set the treatment standards for nasopharyngeal carcinoma, the centre ran the JUPITER-02 toripalimab trial and camrelizumab studies, and it leads trials of izalontamab brengitecan, with Mu-Sheng Zeng, Feng Wang and Rui-Hua Xu also listed. OnCo links it to head and neck, gastric, oesophageal and liver cancers, to plasma EBV DNA, to the idea of blood EBV DNA screening across southern China and Southeast Asia, and to the CSCO guidelines. Whether Chinese trial results are accepted by regulators elsewhere is the open question its work keeps testing. Its nasopharyngeal and ADC programmes are the ones to read.
Location
Guangzhou, CN
Type
cancer center
Website
Newsweek 2026 oncology rank
#60
OnCo score
#108 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Sun Yat-sen University Cancer Center, including child institutions. 1,866 works · 22,263 citations · 75% open access · 16% clinical trials · 1% reviews.
Oncology works per year
3972022
4042023
3762024
4002025
2892026
Most works
- Rui‐Hua Xu67 works
- Wenfeng Fang46 works
- Shusen Wang45 works
- Zhizhong Pan44 works
- Yunpeng Yang38 works
- Mu‐Sheng Zeng38 works
- Hongyun Zhao37 works
- Peirong Ding35 works
- Yuanyuan Zhao34 works
- Yan Huang33 works
Most cited
- Nasopharyngeal carcinoma
- ADC and IO trials
Feng Wang
Professor of Medical Oncology, Sun Yat-sen University Cancer Center
Gastric cancerColorectal cancerImmunotherapy biomarkers
A GI oncologist whose work on immunotherapy biomarkers and Chinese gastric cancer trials feeds global guidelines.
Jun Ma
Professor of Radiation Oncology; nasopharyngeal carcinoma programme, Sun Yat-sen University Cancer Center
Nasopharyngeal carcinomaRadiation oncologyInduction chemotherapy
Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.
Li Zhang
Professor of Medical Oncology; Director, Department of Medical Oncology, Sun Yat-sen University Cancer Center
Lung cancerNasopharyngeal carcinomaImmunotherapy
Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.
Mu-Sheng Zeng
Professor; Director, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
Epstein-Barr virusNasopharyngeal carcinoma biologyViral oncology
Virologist who mapped how Epstein-Barr virus drives nasopharyngeal cancer and is developing vaccines against it.
Rui-Hua Xu
President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology
Gastrointestinal oncologyColorectal cancerOesophageal and gastric cancer
Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.
Wenfeng Fang
Professor of Medical Oncology, Sun Yat-sen University Cancer Center
Lung cancerImmunotherapyNasopharyngeal carcinoma
Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.
Similar pages
- InstitutionCancer Hospital, Chinese Academy of Medical Sciences
Shares CSCO guidelines (China), Chinese Society of Clinical Oncology, National Medical Products Administration / Center for Drug Evaluation, Trials do not represent the people who get cancer.
- TreatmentCamrelizumab
Shares Li Zhang, Wenfeng Fang, Rui-Hua Xu, CAPTAIN-1st.
- TargetARID2
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.
- TrialHARMONi-A
Shares Li Zhang, Wenfeng Fang.
- CompanyCoherus BioSciences
Shares JUPITER-02, Oesophageal cancer, Head and neck squamous cell carcinoma.
- Key paperCONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma
Shares CONTINUUM, Nasopharyngeal carcinoma.
- InstitutionQueen Mary Hospital / University of Hong Kong
Shares Plasma EBV DNA, Hepatocellular carcinoma, Head and neck squamous cell carcinoma.
- IdeaBlended finance and a low-cost linac to close the global radiotherapy gap
Shares Burden-matched funding for trials led in low- and middle-income countries, Most of the world has almost no cancer care, Head and neck squamous cell carcinoma.
cancers
drugs
Phase 3Bispecific ADC